ストックスクリーナーアプリを入手
14.42
12.74%
1.6293
アフターアワーズ：
14.60
0.1784
+1.24%
前日終値:
$12.79
開ける：
$13.78
24時間の取引高:
3,197
Relative Volume:
0.40
時価総額：
$20.90M
収益：
$226.00K
当期純損益:
$-20.18M
株価収益率:
-14.87
EPS:
-0.97
ネットキャッシュフロー:
$-17.40M
1週間 パフォーマンス:
-2.95%
1か月 パフォーマンス:
-20.06%
6か月 パフォーマンス:
+1,349%
1年 パフォーマンス:
+1,349%
1日の値動き範囲:
$13.78
$14.42
1週間の範囲:
$12.78
$15.30
52週間の値動き範囲:
$10.62
$43.14
Onconova Therapeutics Inc Stock (ONTX) Company Profile
Compare ONTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONTX
Onconova Therapeutics Inc
|
14.42 | 20.90M | 226.00K | -20.18M | -17.40M | -0.97 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onconova Therapeutics Inc Stock (ONTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Onconova Therapeutics Inc (ONTX) 最新ニュース
CORGI ONTO 2X DAILY ETF (NASDAQ: ONTX) Stock Price, News & Analysis - Kalkine
Onconova Therapeutics Stock Price Forecast. Should You Buy ONTX? - StockInvest.us
(TRAW) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TRAW - Finviz
Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer - Yahoo Finance
Q4 2025 Traws Pharma Inc Earnings Call Transcript - GuruFocus
TransCode Therapeutics Appoints Jack E. Stover To Board - citybiz
Oncology Clinical Trials Market Size, Share, Growth, Analysis, 2034 - Straits Research
Annovis Appoints Mark Guerin as Chief Financial Officer - citybiz
Rigosertib Shows Promise in EB-Associated Skin Cancer - Medscape
ONTX Stock Price, News & Analysis - Stock Titan
Onconova Therapeutics (NASDAQ: ONTXW)Share Price - intelligentinvestor.com.au
‘Best-In-Class Virology And Oncology’: Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Combine to Form Traws Pharma, Inc. - orrick.com
META_TITLE_QUOTE - Yahoo Finance
Traws Pharma (TRAW) Stock Price, News & Analysis - MarketBeat
10 High-Volume Penny Stocks and Trading Strategies - StocksToTrade
Onconova and Trawsfynydd merge to form Traws Pharma By Investing.com - Investing.com UK
PI3K Inhibitors Clinical Trial Pipeline Experiences - GlobeNewswire
We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully - Yahoo Finance
Zim Doctor Appointed Chief Medical Officer in UK - zimeye.net
Penny Stocks To Buy Now? 5 With Big News Today - PennyStocks.com
Onconova Therapeutics Touts Additional Positive Data For Rigosertib Monotherapy In Skin Cancer Setting - Yahoo Finance
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors - citybiz
Rudolph John Skalka - The Valley Reporter
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022 - The Globe and Mail
Corgi Onto 2X Daily ETF (ONTX-A) Stock Price and News - The Globe and Mail
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug - Yahoo Finance
Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy - EMJ
ONTX stock dives 16%, DVAX stock in green after clinical data - Kalkine Media
What's going on in today's pre-market session - ChartMill
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer - GlobeNewswire
Why Onconova Therapeutics (ONTX) Stock Is Up Sharply - Market Realist
Onconova Therapeutics Begins Rigosertib Study in Rare Squamous Cell Cancer Subgroup - GenomeWeb
Onconova Therapeutics (ONTX) Stock Live Price, Chart & News - CoinCodex
ONTX Stock: Why Biopharma Onconova Therapeutics Is Shooting Higher Today - InvestorPlace
PrimoHoagies is on a roll, adding 21 stores, while Penn-backed Carisma raises cash to fight cancer - Inquirer.com
Novel CDK4/6 Inhibitor ON 123300 Receives Green Light to Move Into Phase 1 Testing in Relapsed/Refractory Advanced Cancers - OncLive
Onconova Therapeutics Appoints James J. Marino, JD, MBA as Chairman of the Board of Directors - citybiz
Onconova Therapeutics Inc Files For Mixed Shelf Of Up To $150 Million - Reuters
ONTX Stock Price, Quote & Chart | ONCONOVA THERAPEUTICS INC (NASDAQ:ONTX) - ChartMill
Bucks County biopharm firm names new CEO - The Business Journals
Onconova Therapeutics Announces New CEO Appointment - Global Banking & Finance Review
Hedge Fund and Insider Trading News: Michael Novogratz, Ray Dalio, Onconova Therapeutics Inc. (ONTX), Cerecor Inc (CERC), Spirit of Texas Bancshares Inc (STXB), L3 Technologies Inc (LLL), and More - Insider Monkey
Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib - Reuters
Onconova Therapeutics Announces Closing of $10 Million - GlobeNewswire
Onconova Therapeutics to Present at Biotech Showcase in January - GlobeNewswire
Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - marketexclusive.com
Onconova Therapeutics Announces Data on Improved - GlobeNewswire
Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio? - Yahoo Finance
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting - GlobeNewswire
Onconova Therapeutics Inc (ONTX) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):